Sudden cardiac death in childhood hypertrophic cardiomyopathy.

[1]  Yong Zhang,et al.  Factors associated with the risk of cardiac death in children with hypertrophic cardiomyopathy: a systematic review and meta-analysis. , 2021, Heart & lung : the journal of critical care.

[2]  E. Fernlund,et al.  Sudden cardiac death in childhood hypertrophic cardiomyopathy is best predicted by a combination of electrocardiogram risk‐score and HCMRisk‐Kids score , 2021, Acta paediatrica.

[3]  J. Kaski,et al.  Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere , 2021, Frontiers in Pediatrics.

[4]  G. Limongelli,et al.  Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes , 2021, Frontiers in Pediatrics.

[5]  B. Maron,et al.  EVOLUTION OF RISK STRATIFICATION AND SUDDEN DEATH PREVENTION IN HYPERTROPHIC CARDIOMYOPATHY: 20 YEARS WITH THE IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR. , 2021, Heart rhythm.

[6]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[7]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[8]  L. Leinwand,et al.  Defining the Cardiac Fibroblast Secretome in a Fibrotic Microenvironment , 2020, Journal of the American Heart Association.

[9]  Fengqin Gao,et al.  A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme , 2020, Molecular therapy. Methods & clinical development.

[10]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[11]  Yusu Gu,et al.  Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease , 2020, Science Translational Medicine.

[12]  A. Carnevale,et al.  Genes frequently associated with sudden death in primary hypertrophic cardiomyopathy. , 2020, Archivos de cardiologia de Mexico.

[13]  P. Elliott,et al.  Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[14]  R. Weintraub,et al.  Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). , 2019, JAMA cardiology.

[15]  A. Schenone,et al.  Infantile-onset Pompe disease: Diagnosis and management. , 2019, Archivos argentinos de pediatria.

[16]  S. Colan,et al.  Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. , 2019, Circulation.

[17]  P. Laforêt,et al.  Progress and challenges of gene therapy for Pompe disease. , 2019, Annals of translational medicine.

[18]  B. Gelb,et al.  Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition. , 2019, Journal of the American College of Cardiology.

[19]  J. Skinner.  Risk Stratification in Hypertrophic Cardiomyopathy: Time to Think about the Electrocardiogram , 2019, Cardiogenetics.

[20]  Joseph Loscalzo,et al.  Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[21]  J. Spudich.  Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations , 2019, Pflügers Archiv - European Journal of Physiology.

[22]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[23]  E. Behr,et al.  Sudden Death Can Be the First Manifestation of Hypertrophic Cardiomyopathy: Data From a United Kingdom Pathology Registry. , 2019, JACC. Clinical electrophysiology.

[24]  I. Olivotto,et al.  Clinical profile and outcome of cardiac involvement in MELAS syndrome. , 2019, International journal of cardiology.

[25]  G. Hindricks,et al.  Prevention of sudden cardiac death by the implantable cardioverter-defibrillator. , 2018, Polish archives of internal medicine.

[26]  I. Nonaka,et al.  A Nationwide Survey on Danon Disease in Japan , 2018, International journal of molecular sciences.

[27]  A. Mugelli,et al.  Altered Ca2+ and Na+ Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis , 2018, Front. Physiol..

[28]  J. Molkentin,et al.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure , 2018, Circulation.

[29]  Amit R. Patel,et al.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy , 2018, Circulation.

[30]  F. Pérez-Villa,et al.  Heart transplantation in patients with hypertrophic cardiomyopathy , 2018, Global cardiology science & practice.

[31]  C. Rapezzi,et al.  Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events , 2018, JAMA cardiology.

[32]  B. Maron,et al.  Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[33]  Pablo Laguna,et al.  Distinct ECG Phenotypes Identified in Hypertrophic Cardiomyopathy Using Machine Learning Associate With Arrhythmic Risk Markers , 2018, Front. Physiol..

[34]  J. Finsterer,et al.  MERRF Classification: Implications for Diagnosis and Clinical Trials. , 2017, Pediatric neurology.

[35]  M. Digilio,et al.  Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. , 2017, International journal of cardiology.

[36]  S. Chugh,et al.  Prevention of Sudden Cardiac Death in Children and Young Adults. , 2017, Progress in pediatric cardiology.

[37]  R. Chan,et al.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients , 2017, Journal of the American Heart Association.

[38]  P. Elliott,et al.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis , 2017, European journal of preventive cardiology.

[39]  Francisco J. Alvarado,et al.  Genotype-Dependent and -Independent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy , 2016, Circulation.

[40]  R. Swaminathan,et al.  Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. , 2016, JAMA cardiology.

[41]  P. Laforêt,et al.  Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome , 2016, Journal of Inherited Metabolic Disease.

[42]  D. Vargas,et al.  Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. , 2016, Radiographics : a review publication of the Radiological Society of North America, Inc.

[43]  L. Selim,et al.  Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group , 2015, BMC Neurology.

[44]  M. Ackerman,et al.  Surgical Ventricular Septal Myectomy for Patients With Noonan Syndrome and Symptomatic Left Ventricular Outflow Tract Obstruction. , 2015, The American journal of cardiology.

[45]  N. Smedira,et al.  Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. , 2015, Journal of the American College of Cardiology.

[46]  F. Scaglia,et al.  MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. , 2015, Molecular genetics and metabolism.

[47]  F. Rutten,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[48]  L. Mestroni,et al.  Danon Disease: Clinical Features, Evaluation, and Management , 2014, Circulation: Heart Failure.

[49]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[50]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[51]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[52]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[53]  Raffaella Lombardi,et al.  Human Molecular Genetic and Functional Studies Identify TRIM63, Encoding Muscle RING Finger Protein 1, as a Novel Gene for Human Hypertrophic Cardiomyopathy , 2012, Circulation research.

[54]  S. Colan,et al.  Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. , 2012, American heart journal.

[55]  J. Kaski,et al.  Hypertrophic cardiomyopathy in children , 2012, Heart.

[56]  J. Towbin,et al.  Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. , 2012, Journal of cardiac failure.

[57]  H. Katus,et al.  Mechanisms of disease: hypertrophic cardiomyopathy , 2012, Nature Reviews Cardiology.

[58]  M. Maron,et al.  Clinical Utility of Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012, Journal of Cardiovascular Magnetic Resonance.

[59]  L. Mestroni,et al.  Sudden death associated with danon disease in women. , 2012, The American journal of cardiology.

[60]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[61]  W. Roberts,et al.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management , 2011, Journal of Inherited Metabolic Disease.

[62]  B. Neel,et al.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. , 2011, The Journal of clinical investigation.

[63]  B. Neel,et al.  Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. , 2011, The Journal of clinical investigation.

[64]  Ingegerd Östman-Smith.  Hypertrophic cardiomyopathy in childhood and adolescence – strategies to prevent sudden death , 2010, Fundamental & clinical pharmacology.

[65]  J. Seidman,et al.  Genetics of hypertrophic cardiomyopathy , 2010, Current opinion in cardiology.

[66]  A. Tajik,et al.  Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. , 2009, Journal of the American College of Cardiology.

[67]  J. Seidman,et al.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. , 2009, JAMA.

[68]  D. Holmgren,et al.  Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. , 2008, European heart journal.

[69]  A. Dipchand,et al.  Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[70]  G. Boriani,et al.  Heart transplantation in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[71]  G. Di Salvo,et al.  Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. , 2007, The American journal of cardiology.

[72]  S. Colan,et al.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2007, Circulation.

[73]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[74]  Barry J Maron,et al.  Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. , 2006, European heart journal.

[75]  P. Elliott,et al.  Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy , 2006, Heart.

[76]  G. Boriani,et al.  Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. , 2005, Journal of the American College of Cardiology.

[77]  Barry J Maron,et al.  Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[78]  M. Kotb,et al.  Liver glycogenoses: are they a possible cause of polyneuropathy? A cross-sectional study. , 2004, Journal of tropical pediatrics.

[79]  N. Smedira,et al.  Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. , 2004, The American journal of cardiology.

[80]  H. Leong,et al.  Glycolysis and pyruvate oxidation in cardiac hypertrophy--why so unbalanced? , 2003, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[81]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[82]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[83]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[84]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[85]  T. Riesenfeld,et al.  A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. , 1999, Journal of the American College of Cardiology.

[86]  B. McCrindle,et al.  Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[87]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[88]  F. Carreras,et al.  Comparison of morphologic assessment of hypertrophic cardiomyopathy by magnetic resonance versus echocardiographic imaging. , 1997, The American journal of cardiology.

[89]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[90]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[91]  R. C. Saumarez,et al.  Ventricular Fibrillation in Hypertrophic Cardiomyopathy Is Associated With Increased Fractionation of Paced Right Ventricular Electrograms , 1992, Circulation.

[92]  B. Maron,et al.  Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy. , 1986, The American journal of cardiology.

[93]  Y. Koga,et al.  Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. , 1986, Japanese heart journal.

[94]  J. Deanfield,et al.  Hypertrophic cardiomyopathy: an important cause of sudden death. , 1984, Archives of disease in childhood.

[95]  W. Roberts,et al.  Hypertrophic Cardiomyopathy in Infants: Clinical Features and Natural History , 1982, Circulation.

[96]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[97]  A. Abdulla,et al.  Long-term medical management of hypertrophic obstructive cardiomyopathy. , 1978, The American journal of cardiology.

[98]  W. Henry,et al.  Operative Treatment in Hypertrophic Subaortic Stenosis: Techniques, and the Results of Pre and Postoperative Assessments in 83 Patients , 1975, Circulation.

[99]  E. W. Hancock,et al.  Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. , 1973, The American journal of cardiology.

[100]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.

[101]  E. Braunwald,et al.  Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. , 1966, The New England journal of medicine.

[102]  E. Braunwald,et al.  Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.

[103]  E. Braunwald,et al.  Studies on Digitalis: V. Comparison of the Effects of Ouabain on Left Ventricular Dynamics in Valvular Aortic Stenosis and Hypertrophic Subaortic Stenosis , 1962, Circulation.

[104]  E. Prescott.  Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. , 2006, European heart journal.

[105]  A. Rigopoulos,et al.  Management of Hypertrophic Cardiomyopathy in Children , 2003, Paediatric drugs.

[106]  A. Munnich,et al.  Heart transplantation in children with mitochondrial cardiomyopathy , 2022 .